Default company panoramic image


Omniox focuses on alleviating disease-causing tissue hypoxia using a breakthrough oxygen carrier technology that overcomes prior failures

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded October 2006
  • Employees 8
  • Website

Company Summary

Omniox is a biotechnology company commercializing a breakthrough oxygen delivery protein technology called H-NOX to address diseases of peripheral hypoxia. Omniox products will be applied to a broad range of unmet clinical needs in cancer, cardiovascular diseases, and trauma. The H-NOX platform directly overcomes key reasons for the failure of prior oxygen delivery efforts, and has the potential to become a transformational medical technology.


  • Default avatar
    Stephen Cary, Ph.D.

    Dr. Cary co-founded Omniox in 2006. He spent five years at Genentech, first in Research on preclinical immunology and oncology disease models and then in Development as a development and market strategist.

  • Default avatar
    Michael Marletta, Ph.D.
    Chair SAB

    Dr. Marletta is the Chair of the Scientific Advisory Board. He is also the President and CEO of The Scripps Research Institute, Ida H. and Cecil M. Green Professor of Chemistry, and is a member of the Institute of Medicine and the National Academy of Sciences.

  • Default avatar
    Ajit Shah, Ph.D.

    Dr. Shah has a combined 24 years of experience as an entrepreneur, operating executive and venture capitalist. He is also the co-founder of Intuitive Surgical and on the UC Berkeley Engineering Advisory Board. Dr. Shah is recognized in Silicon Valley as an outstanding scientific and strategic advisor to start-ups.


  • Default avatar
    Alan Mendelson (L&W) and Gladys Monroy (MoFo)
    Default avatar

Previous Investors

  • Default avatar
    Friends & Family